Inventaire - your friends and communities are your best library - Inventaire

Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis

published in: JHEP Reports

date of publication: 2020-05-29

main subject: belimumab, autoimmune hepatitis

Cites articles 22

Date

Title

Authors

2020-01-07

Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase
2019-11-05

Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group

James Hodson, David Adams
2019-08-30

Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs

Kjartan B Valgeirsson
2019-06-21

The Contribution of B Cells in Autoimmune Liver Diseases
2019-02-13

Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis

Priscila Santiago
2019-01-22

Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop

Jessica K Dyson, George N Dalekos, Piotr Milkiewicz
2018-10-18

Prompt initiation of high-dose i.v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis
2018-09-18

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

Jessica K Dyson, David E. J. Jones
2017-11-24

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis
2017-02-04

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
2016-12-22

Expert clinical management of autoimmune hepatitis in the real world

Piotr Milkiewicz, Pietro Invernizzi
2016-03-01

B-Cell Activating Factor Belonging to the Tumor Necrosis Factor Family and Interferon-γ-Inducible Protein-10 in Autoimmune Hepatitis
2016-03-16

A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis
2015-09-01

EASL Clinical Practice Guidelines: Autoimmune hepatitis
2013-03-23

Use of TNFα antagonists in refractory AIH: revealing the unforeseen
2012-11-07

TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression

Tsutomu Chiba
2012-11-21

Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis

Christoph Schramm
2012-02-09

Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease
2011-08-30

Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate

Shivakumar Chitturi
2011-06-12

The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

Karel van Erpecum
2009-09-18

Aetiopathogenesis of autoimmune hepatitis
Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis

Article - wd:Q97529168

Welcome to Inventaire

the library of your friends and communities

you are offline